Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas
Fariba Ghassemi, 1–3 Shahab Sheibani, 4 Mojtaba Arjmand, 3 Hosein Poorbaygi, 4 Emad Kouhestani, 1 Siamak Sabour, 5 Farhad Samiei, 6 Akbar Beiki-Ardakani, 7 Mahmood Jabarvand, 1 Ali Sadeghi Tari 1 1Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR,...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/82707c159cbc496790efd46e22fde664 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:82707c159cbc496790efd46e22fde664 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:82707c159cbc496790efd46e22fde6642021-12-02T10:56:59ZComparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas1177-5483https://doaj.org/article/82707c159cbc496790efd46e22fde6642020-02-01T00:00:00Zhttps://www.dovepress.com/comparison-of-iodide-125-and-ruthenium-106-brachytherapy-in-the-treatm-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Fariba Ghassemi, 1–3 Shahab Sheibani, 4 Mojtaba Arjmand, 3 Hosein Poorbaygi, 4 Emad Kouhestani, 1 Siamak Sabour, 5 Farhad Samiei, 6 Akbar Beiki-Ardakani, 7 Mahmood Jabarvand, 1 Ali Sadeghi Tari 1 1Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran; 2Retina & Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran; 3Ocular Oncology Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran; 4Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran; 5Safety Promotion and Injury Prevention Research Centre, Department of Clinical Epidemiology, School of Health,Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran; 6Radiation Oncology Department, Cancer Institute, Imam Hospital and Medical Complex, Tehran University of Medical Sciences, Tehran, Iran; 7Radiation Physics Department, Princess Margaret Hospital, Toronto, ON, CanadaCorrespondence: Fariba GhassemiEye Research Center, Farabi Eye Hospital, Qazvin Square, Tehran 1336616351, IranTel +98-21-55421006Fax +98-21-55416134Email fariba.ghassemi@gmail.comBackground: To compare iodine-125 ( 125I) with ruthenium-106 ( 106Ru) episcleral plaque radiation therapy in terms of the effectiveness and non-inferiority for choroidal melanoma treatment.Objective: To report the non-inferiority of new made iodine-125 ( 125I) compared with ruthenium-106 ( 106Ru) episcleral plaque radiation.Patients and Methods: A retrospective, non-randomized comparative case series. In this series the patients treated with 125I and 106Ru episcleral plaques for choroidal melanoma between September 2013 and August 2017 at Farabi Hospital are compared. Local control of choroidal melanomas after 125I and 106Ru plaques implantation and vision changes are the main outcome measures.Results: A total of 35 patients were identified ( 125I = 15, 106Ru = 20). No significant difference between two groups in visual acuity, diameter and thickness changes were observed after treatment. Multivariate linear regression (MLR) analysis showed that final diameter was only, independently and significantly, correlated with the pre-treatment diameter of the tumor (β =  0.59, 95% confidence interval [CI]: 0.29, 1.34, P =  0.003). The same MLR analysis for the final thickness and visual acuity, after adjusting for age and sex showed no significant difference between two groups. A single patient treated with 106Ru had local tumor recurrence with no one in the 125I group. No statistical difference in the rate of ocular complications was observed.Conclusion: The treatment with our 125I plaques is as effective as 106Ru plaques in controlling choroidal melanoma tumor and preserving the vision during the two and half year of follow-up. The complication rates are alike. It means that the effectiveness of 125I is not only comparable to 106Ru but also superior when the outcome of the interest is the thickness of the tumors.Keywords: brachytherapy, choroidal melanoma, complication, local tumor control, 125I, radiation, 106Ru, tumor size, vision preservationGhassemi FSheibani SArjmand MPoorbaygi HKouhestani ESabour SSamiei FBeiki-Ardakani AJabarvand MSadeghi Tari ADove Medical Pressarticlebrachytherapychoroidal melanomacomplicationlocal tumor control125iradiation106rutumor sizevision preservation.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 339-346 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
brachytherapy choroidal melanoma complication local tumor control 125i radiation 106ru tumor size vision preservation. Ophthalmology RE1-994 |
| spellingShingle |
brachytherapy choroidal melanoma complication local tumor control 125i radiation 106ru tumor size vision preservation. Ophthalmology RE1-994 Ghassemi F Sheibani S Arjmand M Poorbaygi H Kouhestani E Sabour S Samiei F Beiki-Ardakani A Jabarvand M Sadeghi Tari A Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas |
| description |
Fariba Ghassemi, 1–3 Shahab Sheibani, 4 Mojtaba Arjmand, 3 Hosein Poorbaygi, 4 Emad Kouhestani, 1 Siamak Sabour, 5 Farhad Samiei, 6 Akbar Beiki-Ardakani, 7 Mahmood Jabarvand, 1 Ali Sadeghi Tari 1 1Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran; 2Retina & Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran; 3Ocular Oncology Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran; 4Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran; 5Safety Promotion and Injury Prevention Research Centre, Department of Clinical Epidemiology, School of Health,Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran; 6Radiation Oncology Department, Cancer Institute, Imam Hospital and Medical Complex, Tehran University of Medical Sciences, Tehran, Iran; 7Radiation Physics Department, Princess Margaret Hospital, Toronto, ON, CanadaCorrespondence: Fariba GhassemiEye Research Center, Farabi Eye Hospital, Qazvin Square, Tehran 1336616351, IranTel +98-21-55421006Fax +98-21-55416134Email fariba.ghassemi@gmail.comBackground: To compare iodine-125 ( 125I) with ruthenium-106 ( 106Ru) episcleral plaque radiation therapy in terms of the effectiveness and non-inferiority for choroidal melanoma treatment.Objective: To report the non-inferiority of new made iodine-125 ( 125I) compared with ruthenium-106 ( 106Ru) episcleral plaque radiation.Patients and Methods: A retrospective, non-randomized comparative case series. In this series the patients treated with 125I and 106Ru episcleral plaques for choroidal melanoma between September 2013 and August 2017 at Farabi Hospital are compared. Local control of choroidal melanomas after 125I and 106Ru plaques implantation and vision changes are the main outcome measures.Results: A total of 35 patients were identified ( 125I = 15, 106Ru = 20). No significant difference between two groups in visual acuity, diameter and thickness changes were observed after treatment. Multivariate linear regression (MLR) analysis showed that final diameter was only, independently and significantly, correlated with the pre-treatment diameter of the tumor (β =  0.59, 95% confidence interval [CI]: 0.29, 1.34, P =  0.003). The same MLR analysis for the final thickness and visual acuity, after adjusting for age and sex showed no significant difference between two groups. A single patient treated with 106Ru had local tumor recurrence with no one in the 125I group. No statistical difference in the rate of ocular complications was observed.Conclusion: The treatment with our 125I plaques is as effective as 106Ru plaques in controlling choroidal melanoma tumor and preserving the vision during the two and half year of follow-up. The complication rates are alike. It means that the effectiveness of 125I is not only comparable to 106Ru but also superior when the outcome of the interest is the thickness of the tumors.Keywords: brachytherapy, choroidal melanoma, complication, local tumor control, 125I, radiation, 106Ru, tumor size, vision preservation |
| format |
article |
| author |
Ghassemi F Sheibani S Arjmand M Poorbaygi H Kouhestani E Sabour S Samiei F Beiki-Ardakani A Jabarvand M Sadeghi Tari A |
| author_facet |
Ghassemi F Sheibani S Arjmand M Poorbaygi H Kouhestani E Sabour S Samiei F Beiki-Ardakani A Jabarvand M Sadeghi Tari A |
| author_sort |
Ghassemi F |
| title |
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas |
| title_short |
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas |
| title_full |
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas |
| title_fullStr |
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas |
| title_full_unstemmed |
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas |
| title_sort |
comparison of iodide-125 and ruthenium-106 brachytherapy in the treatment of choroidal melanomas |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/82707c159cbc496790efd46e22fde664 |
| work_keys_str_mv |
AT ghassemif comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT sheibanis comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT arjmandm comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT poorbaygih comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT kouhestanie comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT sabours comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT samieif comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT beikiardakania comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT jabarvandm comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas AT sadeghitaria comparisonofiodide125andruthenium106brachytherapyinthetreatmentofchoroidalmelanomas |
| _version_ |
1718396408876236800 |